Related Experiment Videos
A direct binding assay for thyrotropin receptor autoantibodies
G D Chazenbalk1, P Pichurin, S M McLachlan
1Autoimmune Disease Unit, Cedars-Sinai Research Institute and School of Medicine, University of California, Los Angeles 90048, USA.
Thyroid : Official Journal of the American Thyroid Association
|December 14, 1999
Summary
A new direct assay for thyrotropin receptor autoantibodies (DTAb) was developed. This assay shows strong correlation with thyrotropin binding inhibition (TBI) and offers potential for Graves' disease diagnosis.
Area of Science:
- Endocrinology
- Immunology
- Assay Development
Background:
- Direct autoantibody binding to the thyrotropin receptor (TSHR) is crucial in Graves' disease pathogenesis.
- Current clinical assays for TSHR autoantibodies lack direct binding measurement.
Purpose of the Study:
- To develop and validate a novel direct thyrotropin receptor autoantibody binding assay (DTAb).
- To assess the correlation of the DTAb assay with existing TSHR autoantibody assays and clinical outcomes.
Main Methods:
- A direct assay (DTAb) was established using a secreted TSHR ectodomain (TSHR-289) captured by patient immunoglobulin G (IgG).
- High-capacity beads were used to capture IgG, followed by colorimetric detection using a biotinylated monoclonal antibody.
- Sera from normal individuals, Graves' disease patients, and Hashimoto's thyroiditis patients were tested.
Main Results:
- The DTAb assay detected TSHR autoantibodies in 76% of Graves' disease patients, with high optical density values.
- A significant correlation was observed between DTAb and thyrotropin binding inhibition (TBI) values (r = 0.881, p < 0.001).
- The DTAb assay showed moderate correlation with thyroid-stimulating antibody (TSAb) assays (r = 0.582, p < 0.001) and identified one case positive only by direct binding.
Conclusions:
- The developed DTAb assay provides a direct measure of TSHR autoantibody binding.
- The DTAb assay correlates more closely with TBI than TSAb assays, suggesting its potential utility in diagnosing and managing Graves' disease.
- Further clinical validation in diverse patient cohorts is warranted to establish the full clinical utility of the DTAb assay.